Cuprina Secures Exclusive FDA Clearance for Dual-Species Maggot Therapy

Cuprina's FDA clearance for a second fly species creates an exclusive competitive advantage, making it the only company authorized to market two different species for maggot debridement therapy. The approval of Lucilia cuprina expands clinical flexibility alongside the previously cleared Lucilia sericata, opening new markets in regions where different species have traditional recognition. This milestone legitimizes maggot therapy in modern medicine, likely attracting broader clinical adoption and investment in this specialized wound-care field.